cardiopulmonary bypass in patients

Abstract Objectives: Aprotinin has been shown to have anti-inflammatory properties, but its effects on the inflammatory reaction to cardiopulmonary bypass remain controversial. This prospective, randomized, double-blind study evaluated the influence of aprotinin on various blood markers of inflammation during and after cardiopulmonary bypass. Methods: Sixty male patients underwent coronary artery bypass grafting. The patients were randomized into 3 groups: a placebo group, a second group receiving 2,000,000 KIU of aprotinin followed by an infusion of 500,000 KIU/h and 2,000,000 KIU in the pump prime, and a third group receiving half this dosage. Measurements of tumor necrosis factor, interleukin 6, interleukin 8, interleukin 10, endotoxin, histamine, complement factors, prekallikrein, and prostaglandin D 2 were obtained at baseline, 30 minutes after study drug loading, 10 minutes after the beginning of cardiopulmonary bypass, before the end of bypass, 4 hours after bypass, and on the first and second postoperative days. Results: Aprotinin had no significant effect on any of these parameters. As expected, aprotinin reduced early blood loss in both treated groups. Conclusions: These results indicate that aprotinin at doses currently used to reduce blood loss has no significant influence on the systemic inflammatory response during moderate hypothermic cardiopulmonary bypass in human subjects, as assessed by the mediators measured in this study.

[1]  J. Vincent,et al.  Association of tumor necrosis factor-2 allele with plasma tumor necrosis factor-alpha levels and mortality from septic shock. , 2001, The American journal of medicine.

[2]  P. Laippala,et al.  Cytokine responses and myocardial injury in coronary artery bypass grafting. , 2001, Scandinavian journal of clinical and laboratory investigation.

[3]  J. Levy,et al.  Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. , 2001, The Annals of thoracic surgery.

[4]  J. Pincemail,et al.  Cytokine release and neutrophil activation are not prevented by heparin-coated circuits and aprotinin administration. , 2000, The Annals of thoracic surgery.

[5]  H. Meisner,et al.  Drew-Anderson technique attenuates systemic inflammatory response syndrome and improves respiratory function after coronary artery bypass grafting. , 2000, The Annals of thoracic surgery.

[6]  S. Wan,et al.  Avoiding cardiopulmonary bypass in multivessel CABG reduces cytokine response and myocardial injury. , 1999, The Annals of thoracic surgery.

[7]  H. Gilliland,et al.  The effect of aprotinin on interleukin‐8 concentration and leukocyte adhesion molecule expression in an isolated cardiopulmonary bypass system , 1999, Anaesthesia.

[8]  H. Meisner,et al.  Does high-dose methylprednisolone in aprotinin-treated patients attenuate the systemic inflammatory response during coronary artery bypass grafting procedures? , 1999, Journal of cardiothoracic and vascular anesthesia.

[9]  G. Hill,et al.  Pump prime only aprotinin inhibits cardiopulmonary bypass-induced neutrophil CD11b up-regulation. , 1999, The Annals of thoracic surgery.

[10]  J. Fortenberry,et al.  Modifying risk for extracorporeal circulation: trial of four antiinflammatory strategies. , 1998, The Annals of thoracic surgery.

[11]  G. Hill,et al.  Aprotinin enhances the endogenous release of interleukin-10 after cardiac operations. , 1998, The Annals of thoracic surgery.

[12]  J. Vincent,et al.  Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. , 1997, Chest.

[13]  J. Murkin.  Cardiopulmonary bypass and the inflammatory response: a role for serine protease inhibitors? , 1997, Journal of cardiothoracic and vascular anesthesia.

[14]  L. Barvais.  Predictive accuracy of intravenous anesthetic drugs. , 1997, Acta anaesthesiologica Belgica.

[15]  K. Watterson,et al.  "Low-dose" aprotinin modifies hemostasis but not proinflammatory cytokine release. , 1997, The Annals of thoracic surgery.

[16]  C. Baufreton,et al.  Clinical outcome after coronary surgery with heparin-coated extracorporeal circuits for cardiopulmonary bypass , 1996, Perfusion.

[17]  S. Rennard,et al.  Aprotinin Reduces Interleukin-8 Production and Lung Neutrophil Accumulation After Cardiopulmonary Bypass , 1996, Anesthesia and analgesia.

[18]  J. Fleming,et al.  The effect of high dose aprotinin therapy on the systemic inflammatory response in a porcine model of cardiopulmonary bypass , 1996, Perfusion.

[19]  G. von Bernuth,et al.  Histamine liberation related to cardiopulmonary bypass in children: possible relation to transient postoperative arrhythmias. , 1996, The Journal of thoracic and cardiovascular surgery.

[20]  S. Ohri.  Systemic inflammatory response and the splanchnic bed in cardiopulmonary bypass , 1996, Perfusion.

[21]  H. Scheld,et al.  Aprotinin diminishes inflammatory processes. , 1996, International journal of cardiology.

[22]  D. Royston.  Preventing the inflammatory response to open-heart surgery: the role of aprotinin and other protease inhibitors. , 1996, International journal of cardiology.

[23]  D. Royston.  Systemic inflammatory responses to surgery with cardiopulmonary bypass , 1996, Perfusion.

[24]  D. Royston.  Coagulation in cardiac surgery. , 1996, Advances in cardiac surgery.

[25]  J. Vincent,et al.  Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men. , 1996, Surgery.

[26]  G. Regel,et al.  Aprotinin Prevents the Development of the Trauma-Induced Multiple Organ Failure in a Chronic Sheep Model , 1996, European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies.

[27]  G. Hill,et al.  Aprotinin and methylprednisolone equally blunt cardiopulmonary bypass-induced inflammation in humans. , 1995, The Journal of thoracic and cardiovascular surgery.

[28]  P. Menasché.  The inflammatory response to cardiopulmonary bypass and its impact on postoperative myocardial function. , 1995, Current opinion in cardiology.

[29]  D. Das,et al.  Influence of steroids on complement and cytokine generation after cardiopulmonary bypass. , 1995, The Annals of thoracic surgery.

[30]  A. Boutten,et al.  Early production of interleukin-10 during normothermic cardiopulmonary bypass. , 1995, The Journal of thoracic and cardiovascular surgery.

[31]  L. Greenfield,et al.  Relationship of the proinflammatory cytokines to myocardial ischemia and dysfunction after uncomplicated coronary revascularization. , 1994, The Journal of thoracic and cardiovascular surgery.

[32]  F. Cantraine,et al.  Predictive accuracy of midazolam in adult patients scheduled for coronary surgery. , 1994, Journal of clinical anesthesia.

[33]  J. Weiler,et al.  Cytokine and complement levels in patients undergoing cardiopulmonary bypass. , 1993, The Journal of thoracic and cardiovascular surgery.

[34]  R. Colman,et al.  Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. , 1993, The Journal of thoracic and cardiovascular surgery.

[35]  S. Westaby.  Aprotinin in perspective. , 1993, The Annals of thoracic surgery.

[36]  K. Shimamoto,et al.  Inhibition of plasma kallikrein with aprotinin in porcine endotoxin shock. , 1993, The Journal of trauma.

[37]  D. Royston.  High-dose aprotinin therapy: a review of the first five years' experience. , 1992, Journal of cardiothoracic and vascular anesthesia.

[38]  David Rovston.  Aprotinin prevents bleeding and has effects on platelets and fibrinolysis , 1991 .

[39]  W. Baumgartner,et al.  Leukocyte depletion ameliorates free radical-mediated lung injury after cardiopulmonary bypass. , 1990, The Journal of thoracic and cardiovascular surgery.

[40]  F. Levi-Schaffer,et al.  Differential release of histamine and prostaglandin D2 in rat peritoneal mast cells activated with peptides. , 1989, International archives of allergy and applied immunology.

[41]  H. Fritz,et al.  Biochemistry and applications of aprotinin, the kallikrein inhibitor from bovine organs. , 1983, Arzneimittel-Forschung.